Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3155)
All Articles published online
|
Nov 21, 2012 (publication date) through Apr 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283 [PMID: 23180949 DOI: 10.3748/wjg.v18.i43.6277] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i43/6277.htm |
| Number | Citing Articles |
| 1 |
Yuan-wang Qiu, Li-hua Huang, Wen-long Yang, Zhen Wang, Bo Zhang, Yi-guang Li, Ting-ting Su, Hong-yan Zhou, Wei Xu, Xue-dong Wang, Ya-ping Dai, Jian-he Gan. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. International Journal of Infectious Diseases 2016; 43: 43 doi: 10.1016/j.ijid.2015.10.019
|
| 2 |
KASL clinical practice guidelines: management of chronic hepatitis B. Clinical and Molecular Hepatology 2016; 22(1): 18 doi: 10.3350/cmh.2016.22.1.18
|
| 3 |
Chang Hyeong Lee. Oral Antiviral Therapy for Chronic Hepatitis B Virus Infection: Is Continuous Treatment Needed?. Gastroenterology & Hepatology: Open Access 2014; 1(1) doi: 10.15406/ghoa.2014.01.00005
|
| 4 |
Keunhee Kang, Ji Hoon Kim. Is HBsAg Loss an Ideal End-point of Oral Antiviral Therapy in Chronic Hepatitis B Patients?. The Korean Journal of Gastroenterology 2014; 63(5): 329 doi: 10.4166/kjg.2014.63.5.329
|
| 5 |
E. Ridruejo, S. Marciano, O. Galdame, M. V. Reggiardo, A. E. Muñoz, R. Adrover, D. Cocozzella, N. Fernandez, C. Estepo, M. Mendizábal, G. A. Romero, D. Levi, T. Schroder, S. Paz, H. Fainboim, O. G. Mandó, A. C. Gadano, M. O. Silva. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. Journal of Viral Hepatitis 2014; 21(8): 590 doi: 10.1111/jvh.12200
|
| 6 |
Mengqi Luo, Bin Zhou, Jinlin Hou, Deke Jiang. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatology Research 2022; 52(4): 337 doi: 10.1111/hepr.13749
|
| 7 |
Naruhiko Nagata, Tatehiro Kagawa, Shunji Hirose, Yoshitaka Arase, Kota Tsuruya, Kazuya Anzai, Koichi Shiraishi, Tetsuya Mine. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0454-z
|
| 8 |
Elia Moreno-Cubero, Robert T Sánchez del Arco, Julia Peña-Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel, Juan Ramón Larrubia. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?. World Journal of Gastroenterology 2018; 24(17): 1825-1838 doi: 10.3748/wjg.v24.i17.1825
|
| 9 |
Margarita Papatheodoridi, George Papatheodoridis. Can we stop nucleoside analogues before HBsAg loss?. Journal of Viral Hepatitis 2019; 26(8): 936 doi: 10.1111/jvh.13091
|
| 10 |
Cristina Pérez‐Cameo, Mònica Pons, Rafael Esteban. New therapeutic perspectives in HBV: when to stop NAs. Liver International 2014; 34(s1): 146 doi: 10.1111/liv.12398
|
| 11 |
Renato Medas, Rodrigo Liberal, Guilherme Macedo. Discontinuation of antiviral therapy in chronic hepatitis B patients. World Journal of Clinical Cases 2021; 9(24): 6979-6986 doi: 10.12998/wjcc.v9.i24.6979
|
| 12 |
Meifang Han, Jiaji Jiang, Jinlin Hou, Deming Tan, Yongtao Sun, Mianzhi Zhao, Qin Ning. Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study. Antiviral Therapy 2016; 21(4): 337 doi: 10.3851/IMP3019
|
| 13 |
Ching‐Chung Lin, Ming‐Jong Bair, Chih‐Jen Chen, Keng‐Han Lee, Ming‐Jen Chen, Chia‐Yuan Liu, Chen‐Wang Chang, Kuang‐Chun Hu, Tai‐Cherng Liou, Shee‐Chan Lin, Horng‐Yuan Wang, Cheng‐Hsin Chu, Shou‐Chuan Shih, Tsang‐En Wang. Off‐treatment efficacy of 3‐year nucleos(t)ide analogues in chronic hepatitis B patients. The Kaohsiung Journal of Medical Sciences 2016; 32(1): 10 doi: 10.1016/j.kjms.2015.11.005
|
| 14 |
Junfeng Lu, Jin’e Li, Yali Liu, Shan Ren, Zhenhuan Cao, Yi Jin, Lina Ma, Chengli Shen, Xinyue Chen, Joerg F. Schlaak. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. PLOS ONE 2015; 10(11): e0141072 doi: 10.1371/journal.pone.0141072
|
| 15 |
Chern Hao Chong, Seng Gee Lim. When can we stop nucleoside analogues in patients with chronic hepatitis B?. Liver International 2017; 37(S1): 52 doi: 10.1111/liv.13314
|
| 16 |
Da-biao Chen, You-ming Chen, Jing Liu, Dong-ying Xie, Cui-rong Lu, Zhan-lian Huang, Rui-hua Zhu, Zhi-liang Gao. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients. Journal of Clinical Virology 2014; 59(1): 50 doi: 10.1016/j.jcv.2013.11.002
|
| 17 |
Yi‐Cheng Chen, Chao‐Wei Hsu, Rong‐Nan Chien. Higher HBeAg‐reversion virological relapse and lower sustained remission after treatment cessation in tenofovir‐treated HBeAg‐positive patients. Journal of Medical Virology 2023; 95(11) doi: 10.1002/jmv.29213
|
| 18 |
Christine I. Wooddell, Adam J. Gehring, Man-Fung Yuen, Bruce D. Given. RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses 2021; 13(4): 581 doi: 10.3390/v13040581
|
| 19 |
Chih‐Chien Yao, Chuan‐Mo Lee, Chao‐Hung Hung, Jing‐Houng Wang, Tsung‐Hui Hu, Sheng‐Nan Lu, Chi‐Sin Changchien, Mei‐Chin Hsu, Chien‐Hung Chen. Combining age and HBsAg level predicts post‐treatment durability of nucleos(t)ide analogue‐induced HBeAg seroconversion. Journal of Gastroenterology and Hepatology 2015; 30(5): 918 doi: 10.1111/jgh.12874
|
| 20 |
Baek Gyu Jun, Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim, Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin Cheon. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B. The Korean Journal of Gastroenterology 2016; 67(1): 28 doi: 10.4166/kjg.2016.67.1.28
|
| 21 |
Florian van Bömmel, Thomas Berg. Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B. Liver International 2018; 38(S1): 90 doi: 10.1111/liv.13654
|
| 22 |
Thomas Berg, Karl-Georg Simon, Stefan Mauss, Eckart Schott, Renate Heyne, Dietmar M. Klass, Christoph Eisenbach, Tania Mara Welzel, Reinhart Zachoval, Gisela Felten, Julian Schulze-zur-Wiesch, Markus Cornberg, Marjoleine L. Op den Brouw, Belinda Jump, Hans Reiser, Lothar Gallo, Tobias Warger, Jörg Petersen. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study. Journal of Hepatology 2017; 67(5): 918 doi: 10.1016/j.jhep.2017.07.012
|
| 23 |
Florian van Bömmel, Thomas Berg. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B. Hepatology Communications 2021; 5(10): 1632 doi: 10.1002/hep4.1708
|
| 24 |
Tse-Ling Fong, Andy Tien, Kahee J. Jo, Danny Chu, Eddie Cheung, Edward A. Mena, Quang-Quoc Phan, Andy S. Yu, Wafa Mohammed, Andrew Velasco, Vinh-Huy LeDuc, Nickolas Nguyen, Steven-Bui Han, Mimi Chang, Ho S. Bae, Yong-Won Cho, Myron J. Tong, Stewart L. Cooper. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Digestive Diseases and Sciences 2015; 60(11): 3465 doi: 10.1007/s10620-015-3775-9
|
| 25 |
Wen-xiong Xu, Qian Zhang, Xiang Zhu, Chao-shuang Lin, You-ming Chen, Hong Deng, Yong-yu Mei, Zhi-xin Zhao, Dong-ying Xie, Zhi-liang Gao, Chan Xie, Liang Peng. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Canadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/1817680
|
| 26 |
Apichat Kaewdech, Pimsiri Sripongpun. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World Journal of Hepatology 2021; 13(9): 1042-1057 doi: 10.4254/wjh.v13.i9.1042
|
| 27 |
Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Henry L.Y. Chan, Maria Buti, Marc G. Ghany, Anuj Gaggar, Jenny C. Yang, George Wu, John F. Flaherty, G. Mani Subramanian, Stephen Locarnini, Patrick Marcellin. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatology Communications 2020; 4(1): 8 doi: 10.1002/hep4.1436
|
| 28 |
Chia-Chi Wang, Kuo-Chih Tseng, Tsai-Yuan Hsieh, Tai-Chung Tseng, Hans Hsienhong Lin, Jia-Horng Kao. Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. American Journal of Gastroenterology 2016; 111(9): 1286 doi: 10.1038/ajg.2016.109
|
| 29 |
George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi, Jörg Petersen. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016; 63(5): 1481 doi: 10.1002/hep.28438
|
| 30 |
Robério Amorim de Almeida Pondé. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Molecular Biology Reports 2021; 48(1): 843 doi: 10.1007/s11033-020-06056-4
|